NEW YORK, Aug. 16-GlaxoSmithKline has agreed to be an early access customer of Zyomyx's line of protein biochips, Zyomyx said today.
Zyomyx has developed biochips and a profiling system that permits researchers to track expression of 30 human cytokines in serum samples. According to the company, the system can be used in drug discovery, target validation, biomarker studies and drug candidate evaluation.
The companies did not reveal financial details of the agreement.
The clinical testing company Specialty Laboratories also has an early access agreement with Zyomyx.